Brief Report
Interferon treatment for corneolimbal squamous dysplasia

https://doi.org/10.1016/S0002-9394(99)80252-9Get rights and content

Purpose:

To report a patient with corneolimbal squamous dysplasia successfully treated with interferon therapy.

Method:

A 78-year-old man had a gelatinous and vascularized lesion involving the left cornea and adjacent limbus. Impression cytology studied with periodic acid—Schiff-hematoxylin stain disclosed severe squamous dysplasia. Topical instillation and subconjunctival injection of interferon alpha-2b was instituted.

Results:

The gelatinous tumor mass involving the cornea and adjacent limbus completely resolved 2 months after interferon treatment. He showed no sign of recurrence during the 10-month follow-up.

Conclusion:

Interferon therapy may be a therapeutic alternative for treating corneolimbal squamous dysplasia.

References (5)

There are more references available in the full text version of this article.

Cited by (32)

  • Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia

    2019, American Journal of Ophthalmology
    Citation Excerpt :

    Since then, several studies encompassing 332 individuals have evaluated its use as a primary agent in OSSN, again with a high frequency of resolution (average 95%, range 75%-100%). Similar to 5FU, recurrences were uncommon (range 4%-20%) and most occurred in the first year.3,20,28,29,31–37 Our 81% frequency of resolution fits well within this range.

  • Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia Presented Cornea Society/Fall Educational Symposium, November 2015, Las Vegas, Nevada.

    2016, Ophthalmology
    Citation Excerpt :

    In our study, representing the largest group of patients treated with 5-FU as primary therapy to date, we found that 82% of patients experienced complete resolution of OSSN. Our response frequency of 82% for 5-FU is similar to what has been reported in larger series of IFN- and MMC-treated patients.11,20–26,28–35 One issue in comparing treatment response between 5-FU studies is that varying regimens have been used to treat OSSN.

  • Local chemotherapeutic agents for the treatment of ocular malignancies

    2014, Survey of Ophthalmology
    Citation Excerpt :

    The use of IFN-α2b in the treatment of OSSN was first attempted by Maskin et al in their patient who had regression of a recurrent limbal epithelial lesion previously treated with surgical excision and cryotherapy.97 Later, Hu et al demonstrated that both subconjunctival and topical therapy resulted in clinical resolution of a dysplastic squamous lesion after 2 months of treatment.72 IFN-α2b may be effective when prior surgical excision, cryotherapy, and MMC have failed.70,111

  • Topical Interferon or Surgical Excision for the Management of Primary Ocular Surface Squamous Neoplasia

    2008, Ophthalmology
    Citation Excerpt :

    All deep, lateral, and posterior surgical margins were tumor free by histopathology. Successful use of topical interferon alfa-2b as sole therapy for primary OSSN was previously reported in 15 patients in 5 previously published series (Table 3),50–52,55,58 with only 1 patient observed for more than 16 months.51 Our 13 patients successfully treated with topical interferon alfa-2b for primary OSSN bring the total number of patients in the published literature with primary OSSN successfully treated with topical interferon alfa-2b to 28, with a median disease-free follow-up of 12.5 months (data not shown).

View all citing articles on Scopus
*

Inquiries to Fung-Rong Hu, MD, Department of Ophthalmology, National Taiwan University Hospital, 7 Chung-Shan S Road, Taipei, Taiwan; fax: 886-2-3412875.

View full text